![FibroGen, Inc. logo](/logos/FGEN.webp)
FibroGen, Inc.
NASDAQ:FGEN
Overview | Financials
Company Name | FibroGen, Inc. |
Symbol | FGEN |
Currency | USD |
Price | 0.39 |
Market Cap | 39,156,390 |
Dividend Yield | 0% |
52-week-range | 0.33 - 2.93 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thane Wettig |
Website | https://www.fibrogen.com |
An error occurred while fetching data.
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD